Wang Xiao-Ming, Yin Zhen-Yu, Yu Ren-Xiang, Peng You-Yuan, Liu Ping-Guo, Wu Guo-Yang
Department of Hepatobillary Surgery, Zhongshan Hospital, Digestive Disease Institute, Xiamen University, South Hubin Road #209, Xiamen 361004, Fujian Province, China.
World J Gastroenterol. 2008 Jan 28;14(4):518-23. doi: 10.3748/wjg.14.518.
To evaluate the preventive effects of phosphorus-32 glass microspheres (P32-GMS) in the recurrence of massive hepatocellular carcinomas (HCCs) after tumor resection.
Twenty-nine patients with massive HCCs received local P32-GMS implantation after liver tumors were removed, while the other 38 patients with massive HCCs were not treated with P32-GMS after hepatectomies. The radioactivity of the blood, urine and liver were examined. The complications, HCC recurrence and overall survival rates in the patients were analyzed.
P32-GMS implanted in the liver did not cause systemic absorption of P32. There were no significant differences of postoperative complications between the patients with and without P32-GMS treatment. The short-term (six months and 1 year) and long-term (2, 3 and over 3 years) recurrence rates in patients who received P32-GMS radiotherapy were significantly decreased, and the overall survival rates in this group were significantly improved.
P32-GMS implantation in the liver can significantly decrease the postoperative recurrence and improve the overall survival in HCCs patients after hepatectomy. This therapy may provide an innovative method in prevention of HCC recurrence after operation.
评估磷-32玻璃微球(P32-GMS)对巨大肝细胞癌(HCC)肿瘤切除术后复发的预防作用。
29例巨大HCC患者在肝肿瘤切除后接受局部P32-GMS植入,另外38例巨大HCC患者肝切除术后未接受P32-GMS治疗。检测血液、尿液和肝脏的放射性。分析患者的并发症、HCC复发率和总生存率。
肝脏植入P32-GMS未引起P32的全身吸收。接受和未接受P32-GMS治疗的患者术后并发症无显著差异。接受P32-GMS放射治疗患者的短期(6个月和1年)和长期(2年、3年及3年以上)复发率显著降低,该组患者的总生存率显著提高。
肝脏植入P32-GMS可显著降低HCC患者肝切除术后的复发率并提高总生存率。该治疗方法可能为预防术后HCC复发提供一种创新方法。